Arvinas' ARV-102 linked to improved eye movement control in Phase 1 study
Written by Andrea Lobo | Oct. 14, 2026
- ARV-102 successfully crossed the blood-brain barrier, reduced LRRK2 levels, and improved eye movement in a Phase 1 trial.
- The results build on earlier data showing promise for the experimental treatment.
- The drug's developer said the study supports further clinical evaluation of ARV-102.
Phase 1 trial results showed an experimental oral therapy was associated with improved eye movement control, lower levels of neuroinflammatory biomarkers, and higher markers of nerve cell health in people with Parkinson’s disease.
The results from the ARV-102-103 trial (EUCT 2024-516888-84-00) build on findings presented earlier this year showing that Arvinas‘ ARV-102 reached the brain and reduced levels of its target protein, LRRK2, in the cerebrospinal fluid (CSF, the fluid that surrounds the brain and spinal cord). ARV-102 was also found to be generally safe and well tolerated.
The findings were shared at the Movement Disorders Society International Congress of Parkinson’s Disease and Movement Disorders, held last week in Seoul, South Korea. The data were presented as late-breaking oral and poster presentations titled “Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data.”
“Although this study was not designed to assess clinical efficacy, we are encouraged by the exploratory dose-related changes in [abnormal eye movements] and their associations with LRRK2 degradation and changes in pathway biomarkers,” Ilaria Conti, MD, PhD, Arvinas’ vice president of clinical research, said in a company press release. “These findings support further clinical evaluation of ARV-102.”
Mutations in the LRRK2 gene, which encodes a protein of the same name, are one of the most common genetic causes of Parkinson’s. LRRK2 is often overactive in Parkinson’s, which can disrupt waste recycling within cells and exacerbate inflammation, causing damage to nerve cells.
Recent Comments